VectorY bags $83.5M for antibody gene therapies in neurodegenerative diseases

VectorY Therapeutics added €74.5 million ($83.5 million) to its Series A to fund a gene therapy that makes antibodies in the brain. The biotech’s lead asset VTx-002 is in a